NeurologyNeurology
NAPLEX
PG 89
Drugs used for Convulsive Disorders
Drugs used for Convulsive Disorders
NAPLEX
PG 89
The medication lorazepam (Ativan) has which of the following pharmacological activities?
a. sedative/hypnotic
b. anticonvulsant
c. muscle relaxant
d. anxiolytic
e. all of the above
The medication lorazepam (Ativan) has which of the following pharmacological activities?
a. sedative/hypnotic
b. anticonvulsant
c. muscle relaxant
d. anxiolytic
e. all of the above
The medication lorazepam (Ativan) has which of the following pharmacological activities?
a. sedative/hypnotic
b. anticonvulsant
c. muscle relaxant
d. anxiolytic
e. all of the above
The medication lorazepam (Ativan) has which of the following pharmacological activities?
a. sedative/hypnotic
b. anticonvulsant
c. muscle relaxant
d. anxiolytic
e. all of the above
Major Types of Convulsive Disorders
Major Types of Convulsive Disorders
• Partial – generally involves only one hemisphere of the brain (initially) and asymmetrical:
Simple-no loss of consciousness
Complex-loss of consciousness
Phenytoin, carbamazepine, barbiturates, valproate
• Generalized – generally involves both hemispheres of the brain; bilateral/symmetrical:
absence, myoclonic, clonic, tonic, tonic-clonic,
Valproate, lamotrigine, carbamazepine, ethosuximide
• Status epilepticus—30 minutes of continuous seizures or five
minutes of convulsive seizures.
Lorazepam is drug of choice; midazolam or propofol
• Partial – generally involves only one hemisphere of the brain (initially) and asymmetrical:
Simple-no loss of consciousness
Complex-loss of consciousness
Phenytoin, carbamazepine, barbiturates, valproate
• Generalized – generally involves both hemispheres of the brain; bilateral/symmetrical:
absence, myoclonic, clonic, tonic, tonic-clonic,
Valproate, lamotrigine, carbamazepine, ethosuximide
• Status epilepticus—30 minutes of continuous seizures or five
minutes of convulsive seizures.
Lorazepam is drug of choice; midazolam or propofol
PG 89
Anticonvulsant DrugsAnticonvulsant Drugs AED monotherapy is preferred, but some patients do
require combination therapy. First-line AEDs for partial seizures include carbamazepine,
phenytoin, lamotrigine, valproic acid, and oxcarbazepine.
First-line AEDs for generalized absence seizures include valproic acid and ethosuximide.
First-line AEDs for tonic-clonic seizures include phenytoin, carbamazepine, and valproic acid.
Alternative AEDs include gabapentin, topiramate, levetiracetam, zonisamide, tiagabine, primidone, felbamate, lamotrigine, and phenobarbital.
AED monotherapy is preferred, but some patients do require combination therapy. First-line AEDs for partial seizures include carbamazepine,
phenytoin, lamotrigine, valproic acid, and oxcarbazepine.
First-line AEDs for generalized absence seizures include valproic acid and ethosuximide.
First-line AEDs for tonic-clonic seizures include phenytoin, carbamazepine, and valproic acid.
Alternative AEDs include gabapentin, topiramate, levetiracetam, zonisamide, tiagabine, primidone, felbamate, lamotrigine, and phenobarbital.
PG 89-91
PG 89-91
PG 89-91
Which of the following medications is NOT an inducer of the liver CYP450 system?
a. carbamazepineb. phenytoinc. valproate
d. olanzapinee. phenobarbital
Which of the following medications is NOT an inducer of the liver CYP450 system?
a. carbamazepineb. phenytoinc. valproate
d. olanzapinee. phenobarbital
Which of the following medications is NOT an inducer of the liver CYP450 system?
a. carbamazepineb. phenytoinc. valproate
d. olanzapinee. phenobarbital
Which of the following medications is NOT an inducer of the liver CYP450 system?
a. carbamazepineb. phenytoinc. valproate
d. olanzapinee. phenobarbital
Valproic acid is available in which of the following dosage forms?
I. CapsulesII. LiquidIII. Tablets
a. I onlyb. III onlyc. I and II onlyd. II and III onlye. I, II, and III
Valproic acid is available in which of the following dosage forms?
I. CapsulesII. LiquidIII. Tablets
a. I onlyb. III onlyc. I and II onlyd. II and III onlye. I, II, and III
Valproic acid is available in which of the following dosage forms?
I. CapsulesII. LiquidIII. Tablets
a. I onlyb. III onlyc. I and II onlyd. II and III onlye. I, II, and III
Valproic acid is available in which of the following dosage forms?
I. CapsulesII. LiquidIII. Tablets
a. I onlyb. III onlyc. I and II onlyd. II and III onlye. I, II, and III
A drug specific for petit mal is:
a. clonazepam
b. diazepam
c. flurazepam
d. lorazepam
e. oxazepam
A drug specific for petit mal is:
a. clonazepam
b. diazepam
c. flurazepam
d. lorazepam
e. oxazepam
A drug specific for petit mal is:
a. clonazepam
b. diazepam
c. flurazepam
d. lorazepam
e. oxazepam
A drug specific for petit mal is:
a. clonazepam
b. diazepam
c. flurazepam
d. lorazepam
e. oxazepam
Drugs to Treat Parkinson’s Disease
Drugs to Treat Parkinson’s Disease
NAPLEX
PG 92
PG 92
Drugs to Treat Parkinson Disease
Causes of Parkinson disease
Disruption of dopaminergic / cholinergic balance
Characteristics of patients (TRAP)
Slow onset; Tremor, Rigidity, Akinesia, Postural instability
Drug therapy
Goals – Mainly palliative; attempt to inhibit cholinergic and attenuate dopaminergic action
PG 92
Drugs to Treat Parkinson Disease (cont’d)
Anticholinergic Drugs. Watch for dry mouth, constipation, urinary retention, intraoccular pressure
• Trihexyphenidyl (Artane)
• Benztropine (Cogentin)
• Biperiden (Akineton)
• Diphenhydramine (Benadryl)
Bradykinesia is best defined as:
a. slow movements
b. rapid heart rate
c. narrowing of the pupil
d. excessive sweating
e. loss of desire for pleasurable
activities
Bradykinesia is best defined as:
a. slow movements
b. rapid heart rate
c. narrowing of the pupil
d. excessive sweating
e. loss of desire for pleasurable
activities
Bradykinesia is best defined as:
a. slow movementsb. rapid heart rate (tachycardia)
c. narrowing of the pupil (miosis)
d. excessive sweating (diaphoresis)
e. loss of desire for pleasurable
activities (anhedonia)
Bradykinesia is best defined as:
a. slow movementsb. rapid heart rate (tachycardia)
c. narrowing of the pupil (miosis)
d. excessive sweating (diaphoresis)
e. loss of desire for pleasurable
activities (anhedonia)
PG 92-93
Drugs to Treat Parkinson Disease (cont’d)
Dopaminergic Agents
• Levodopa (Larodopa, Dopar) - watch for on-off effect and vitamin B6 decreases efficacy, iron increases absorption, nausea
• Levodopa/carbidopa (Sinemet) - wait 8 hours if converting from
levodopa. Cut levodopa dose to 25% of original.
• Amantadine (Symmetrel) - increases release of dopamine stores (hypersensitivity); antiviral properties - antiviral for flu
• Ergot-derived dopamine receptor agonists - stimulate dopamine
receptors; (a) bromocriptine mesylate (Parlodel), and (b)
pergolide mesylate (Permax)—withdrawn from market
PG 93
Drugs to Treat Parkinson Disease (cont’d)
• Nonergot dopamine receptor agonists - stimulate dopamine
receptors; (a) pramipexole (Mirapex), (b) ropinirole (Requip), and
(c) rotigotine (Neupro Transdermal)
--- ropinirole approved for Restless Leg Syndrome
• COMT inhibitors - adjunct that extends the action of
levodopa/carbidopa; (a) Tolcapone (Tasmar), monitor hepatic
function, and (b) entacapone (Comtan), combo with Sinemet (Stalevo)
---no monotherapy
• MAO-B inhibitor-adjunct that decreases breakdown of dopamine; (a) selegiline (Eldepryl, Emsam, Zelapar), (b) rasagiline (Azilect)
---watch for MAO-inhibitor drug interactions
•Dopamine agonist for rescue; apomorphine (Apokyn)
What information should the doctor know prior to initiating Mirapex in a patient with Parkinson’s Disease?
I. Decrease the levodopa dose by 20-30% when initiating Mirapex
II. Patient must wear patch for 24 hours for efficacy
III. Monitor for serious cardiac side effects
a. I only
b. III only
c. I and II only
d. II and III only
e. I, II, III
What information should the doctor know prior to initiating Mirapex in a patient with Parkinson’s Disease?
I. Decrease the levodopa dose by 20-30% when initiating Mirapex
II. Patient must wear patch for 24 hours for efficacy
III. Monitor for serious cardiac side effects
a. I only
b. III only
c. I and II only
d. II and III only
e. I, II, III
What information should the doctor know prior to initiating Mirapex in a patient with Parkinson’s Disease?
I. Decrease the levodopa dose by 20-30% when initiating Mirapex
II. Patient must wear patch for 24 hours for efficacy
III. Monitor for serious cardiac side effects
a. I only
b. III only
c. I and II only
d. II and III only
e. I, II, III
What information should the doctor know prior to initiating Mirapex in a patient with Parkinson’s Disease?
I. Decrease the levodopa dose by 20-30% when initiating Mirapex
II. Patient must wear patch for 24 hours for efficacy
III. Monitor for serious cardiac side effects
a. I only
b. III only
c. I and II only
d. II and III only
e. I, II, III
Alzheimer's DrugsAlzheimer's Drugs
NAPLEX
p. 121
Drugs for Alzheimer’s Disease
Cholinesterase inhibitors: all enhance cholinergic activity• Donepezil (Aricept)• Galantamine (Razadyne) (Reminyl – D/C))• Rivastigmine (Exelon)
Glutamate antagonists• Memantine (Namenda)
Miscellaneous agents• Vitamin E• Selegiline (Eldepryl)
p. 121
Cholinesterase Inhibitors DosingCholinesterase Inhibitors Dosing
Drug Starting dose
Time before Increasing dose
Increase dose by
Max dose
Donepezil (Aricept)
5mg QHS 6 weeks 5mg QHS 10mg QHS
Rivastigmine (Exelon)
1.5mg BID 2 weeks 1.5mg BID
6mg BID
Galantamine (Razadyne)
4mg BID 4 weeks 4mg BID Recommen-ded range of 16-24 mg a day.
• Dose dependent side effects require titration• Start low and take steps to avoid side effects
p. 121
Drugs for Alzheimer’s Disease
Adverse Effects
Cholinesterase inhibitors:• Hepatotoxicity• Cholinergic effects (N/D, anorexia, salivation)• Bradycardia• Headache
Glutamate antagonists• Hypertension• Tachycardia• Insomnia
p. 121
Reference Sources for Pharmacists
Reference Sources for Pharmacists
NAPLEX
PG 413PG
Literature ReviewLiterature Review Primary literature Original journal articles
(research reports, case reports, editorials); serves as information for development of secondary and tertiary literature resources
Secondary literature Indexing and abstracting services (e.g. MEDLINE, IPA, EMBASE, Cochrane)
Tertiary literature Textbooks and review articles; summarize and interpret primary literature
Primary literature Original journal articles (research reports, case reports, editorials); serves as information for development of secondary and tertiary literature resources
Secondary literature Indexing and abstracting services (e.g. MEDLINE, IPA, EMBASE, Cochrane)
Tertiary literature Textbooks and review articles; summarize and interpret primary literature
PG 413
ReferencesReferences
USP-NF Official monographs for drug structure, solubilities, assays
and therapeutic category Limited info on dosage, dosage forms
USP DI (Micromedex) Three volume set
• I---DI for healthcare professionals (“package insert”) 11,000 drug products
• II---Advice for patients – easy to understand• III---Approved Drug products, legal requirements, Orange book
FDA Orange Book (electronic - 2004) Bioequivalence information
USP-NF Official monographs for drug structure, solubilities, assays
and therapeutic category Limited info on dosage, dosage forms
USP DI (Micromedex) Three volume set
• I---DI for healthcare professionals (“package insert”) 11,000 drug products
• II---Advice for patients – easy to understand• III---Approved Drug products, legal requirements, Orange book
FDA Orange Book (electronic - 2004) Bioequivalence information
PG 413
ReferencesReferences
Remington’s “Pharmacy encyclopedia” – pharmacology, theoretical
science, sterilization, practical pharmacy practice
Facts and Comparisons Rx and OTC by therapeutic category – monthly updates
AHFS Good info on drug pharmacology – intended for institutional
Blue Book / Red Book Drugs / OTC / Cosmetics Prices, NDC numbers, manufacturer address
Remington’s “Pharmacy encyclopedia” – pharmacology, theoretical
science, sterilization, practical pharmacy practice
Facts and Comparisons Rx and OTC by therapeutic category – monthly updates
AHFS Good info on drug pharmacology – intended for institutional
Blue Book / Red Book Drugs / OTC / Cosmetics Prices, NDC numbers, manufacturer address
PG 414
ReferencesReferences Physician’s Desk Reference (PDR)
White pages—manufacturer index of products Pink pages—product names by trade name Blue pages—products by therapeutic category Yellow pages—generic and trade names with colored product
ID Martindale’s
Comprehensive drug lists (think foreign products) Merck Manual
Describes diseases by symptoms Merck Index
Listing of chemicals Drugs in Pregnancy and Lactation (Briggs)
Gold standard
Physician’s Desk Reference (PDR) White pages—manufacturer index of products Pink pages—product names by trade name Blue pages—products by therapeutic category Yellow pages—generic and trade names with colored product
ID Martindale’s
Comprehensive drug lists (think foreign products) Merck Manual
Describes diseases by symptoms Merck Index
Listing of chemicals Drugs in Pregnancy and Lactation (Briggs)
Gold standard
PG 414
A comparison of the relative daily cost of six brands of HCTZ can most easily be obtained by using the:
a. Martindale’s Extra Pharmacopeia b. Facts and Comparisons
c. Red Book/Blue Book d. Merck Index
e. Remington’s
A comparison of the relative daily cost of six brands of HCTZ can most easily be obtained by using the:
a. Martindale’s Extra Pharmacopeia b. Facts and Comparisons
c. Red Book/Blue Book d. Merck Index
e. Remington’s
A comparison of the relative daily cost of six brands of HCTZ can most easily be obtained by using the:
a. Martindale’s Extra Pharmacopeia (drug lists foreign)
b. Facts and Comparisons (therapuetics)
c. Red Book/Blue Book (prices & NDCs)
d. Merck Index (list of chemicals)
e. Remington’s (pharmacology)
A comparison of the relative daily cost of six brands of HCTZ can most easily be obtained by using the:
a. Martindale’s Extra Pharmacopeia (drug lists foreign)
b. Facts and Comparisons (therapuetics)
c. Red Book/Blue Book (prices & NDCs)
d. Merck Index (list of chemicals)
e. Remington’s (pharmacology)
Which of the following items is NOT presented in USP DI Volume III:
a. Description of therapeutic uses for drugs
b. List of orphan drugs
c. Description of good pharmacy compounding practices
d. Definition of official storage conditions
e. The Federal Controlled Substances Act
Which of the following items is NOT presented in USP DI Volume III:
a. Description of therapeutic uses for drugs
b. List of orphan drugs
c. Description of good pharmacy compounding practices
d. Definition of official storage conditions
e. The Federal Controlled Substances Act
Which of the following items is NOT presented in USP DI Volume III:
a. Description of therapeutic uses for drugsb. List of orphan drugs (Martidale)
c. Description of good pharmacy compounding practices (“a handbook on compounding”)
d. Definition of official storage conditions(Remington's or AHFS)
e. The Federal Controlled Substances Act (Guide to Federal Pharmacy Law)
Which of the following items is NOT presented in USP DI Volume III:
a. Description of therapeutic uses for drugsb. List of orphan drugs (Martidale)
c. Description of good pharmacy compounding practices (“a handbook on compounding”)
d. Definition of official storage conditions(Remington's or AHFS)
e. The Federal Controlled Substances Act (Guide to Federal Pharmacy Law)
Compilation of information concerning parenteral drug solutions are found in:
a. Goodman and Gilman
b. Martindale’s
c. Merck Index
d. Remington’s
e. Trissel’s
Compilation of information concerning parenteral drug solutions are found in:
a. Goodman and Gilman
b. Martindale’s
c. Merck Index
d. Remington’s
e. Trissel’s
Compilation of information concerning parenteral drug solutions are found in:
a. Goodman and Gilman
b. Martindale’s
c. Merck Index
d. Remington’s
e. Trissel’s
Compilation of information concerning parenteral drug solutions are found in:
a. Goodman and Gilman
b. Martindale’s
c. Merck Index
d. Remington’s
e. Trissel’s
Solubility data for potassium gluconate will be found in:
I. Merck IndexII. USP-NFIII. Remington’s
a. I onlyb. III onlyc. I and II onlyd. II and III onlye. I, II, and III
Solubility data for potassium gluconate will be found in:
I. Merck IndexII. USP-NFIII. Remington’s
a. I onlyb. III onlyc. I and II onlyd. II and III onlye. I, II, and III
Solubility data for potassium gluconate will be found in:
I. Merck IndexII. USP-NFIII. Remington’s
a. I onlyb. III onlyc. I and II onlyd. II and III onlye. I, II, and III
Solubility data for potassium gluconate will be found in:
I. Merck IndexII. USP-NFIII. Remington’s
a. I onlyb. III onlyc. I and II onlyd. II and III onlye. I, II, and III
Contraindications for a commercial prescription drug may be located in:
I. PDRII. Merck ManualIII. USP-NF
a. I onlyb. III onlyc. I and II onlyd. II and III onlye. I, II, and III
Contraindications for a commercial prescription drug may be located in:
I. PDRII. Merck ManualIII. USP-NF
a. I onlyb. III onlyc. I and II onlyd. II and III onlye. I, II, and III
Contraindications for a commercial prescription drug may be located in:
I. PDRII. Merck ManualIII. USP-NF
a. I onlyb. III onlyc. I and II onlyd. II and III onlye. I, II, and III
Contraindications for a commercial prescription drug may be located in:
I. PDRII. Merck ManualIII. USP-NF
a. I onlyb. III onlyc. I and II onlyd. II and III onlye. I, II, and III